Elastagen

Sydney, Australia Founded: 2003 • Age: 23 yrs Acquired By Allergan
Company offering solutions for cell growth and tissue repair through their Elastin technology

About Elastagen

Elastagen is a Healthcare company based in Sydney (Australia) founded in 2003, and was acquired by Allergan in February 2018. Company offering solutions for cell growth and tissue repair through their Elastin technology. Elastagen has raised $14.68 million across 6 funding rounds from investors including Korea Investment Holdings, Allergan and AmorePacific. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified.

Company details

Elastagen was founded in 2003 in Sydney, Australia, as a clinical-stage medical company specializing in tropoelastin-based formulations for tissue repair and cell growth. A pipeline of products is developed using recombinant human tropoelastin, with ongoing pivotal clinical studies for an injectable dermo-aesthetic treatment aimed at restoring skin elasticity. Investigations are also conducted into applications for atrophic scars, scar revision, and wound healing. Operations extend to Europe and the UK.

  • Headquarters Sydney, Australia
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website elastagen.com
  • Social LinkedIn X
  • Acquired by Allergan (Feb 2018)
Key Metrics

Funding Insights of Elastagen

Elastagen has successfully raised a total of $14.68M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $4 million completed in October 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $14.68M
  • Total Rounds 6
  • Last Round Grant β€” $4M
  • Investors Count 8

All 6 funding rounds of Elastagen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2016$4MGrant––
–
Jun 2016$744,830Series B––
Jan 2016$9.23MSeries B–Wellcome Trust, AmorePacific
Jul 2013$2MGrant––
Aug 2008$4.7MSeries A––
Jun 2005Seed––
Valuation history

9 investors in total: 9 institutional.

Investors in Elastagen

Elastagen has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Korea Investment Holdings, Allergan and AmorePacific.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
gbsventures.com.au
Early-stage medical companies are funded by this venture capital firm.
brandoncapital.vcMelbourne, Australia
Investment holding firm established in Seoul in 2003.
2003koreainvestment.comSeoul, South Korea
cell-ip.com
Wellcome is a global charitable foundation focused on health research.
wellcome.ac.ukLondon, United Kingdom
atp-innovations.com.au
Beauty products are manufactured and exported by AmorePacific.
1945amorepacific.comSeoul, South Korea
NSW Health is tasked with providing public health services across New South Wales.
health.nsw.gov.auSt Leonards, Australia
A portfolio of generic medicines is developed and manufactured.
1948allergan.comMadison, United States
Premium access

Investor details for Elastagen

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Elastagen

4 dated milestones of Elastagen across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded Elastagen is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Grant, of $4.0M.
  4. Exit Acquired by Allergan.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Elastagen

Premium access

Complete news archive for Elastagen

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Elastagen

Elastagen was founded in 2003 and raised its 1st funding round 2 years after it was founded.

Elastagen is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

Elastagen is a funded company, having raised a total of $14.68M across 6 funding rounds to date.

Elastagen was founded in 2003 in Sydney, Australia, as a clinical-stage medical company specializing in tropoelastin-based formulations for tissue repair and cell growth. A pipeline of products is developed using recombinant human tropoelastin, with ongoing pivotal clinical studies for an injectable dermo-aesthetic treatment aimed at restoring skin elasticity. Investigations are also conducted into applications for atrophic scars, scar revision, and wound healing. Operations extend to Europe and the UK.

Elastagen has 9 investors. Key investors include Korea Investment Holdings, Allergan, AmorePacific, Wellcome, and GBS.

Yes. Elastagen was acquired by Allergan in February 2018.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available